Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...

Long-term oxygen therapy not beneficial for COPD with moderate desaturation. What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 ...

—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...

Please provide your email address to receive an email when new articles are posted on . Risk estimation was based on area under the receiver operating characteristic curve, sensitivity and specificity ...

Please provide your email address to receive an email when new articles are posted on . Minimum pitch in the morning was significantly higher at exacerbation onset and peak vs. baseline. In the ...

Dupilumab is the first biologic to significantly improve lung function in chronic obstructive pulmonary disease (COPD), according to topline results released Thursday. A pivotal phase 3 trial of ...

telemedicine Researchers examined the risks for pneumonia and exacerbation of COPD after PPI treatment for GERD. The risk for symptom exacerbation reduced after PPI treatment for patients with GERD ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

Clinical guidelines recommend use of exacerbation history in choosing therapies to predict the risk for chronic obstructive pulmonary disease exacerbations, but an analysis of data from three ...

Poor quality of sleep was found to have a strong association with symptomatic exacerbations of chronic obstructive pulmonary disease, according to a recent Canadian study presented at the 2016 ...

Results from 2 COPD phase 3 trials suggest that targeting the IL-33 pathway with tozorakimab delivers meaningful clinical benefit.